AQST
Price
$3.52
Change
+$0.10 (+2.92%)
Updated
Jan 14 closing price
Capitalization
429.45M
54 days until earnings call
Intraday BUY SELL Signals
GNMLF
Price
$1.06
Change
-$0.00 (-0.00%)
Updated
Dec 16 closing price
Capitalization
954.09M
Intraday BUY SELL Signals
Interact to see
Advertisement

AQST vs GNMLF

Header iconAQST vs GNMLF Comparison
Open Charts AQST vs GNMLFBanner chart's image
Aquestive Therapeutics
Price$3.52
Change+$0.10 (+2.92%)
Volume$7.09M
Capitalization429.45M
Genomma Lab International SAB DE CV
Price$1.06
Change-$0.00 (-0.00%)
Volume$150
Capitalization954.09M
AQST vs GNMLF Comparison Chart in %
View a ticker or compare two or three
VS
AQST vs. GNMLF commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and GNMLF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (AQST: $3.52 vs. GNMLF: $1.06)
Brand notoriety: AQST and GNMLF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 178% vs. GNMLF: 2%
Market capitalization -- AQST: $429.45M vs. GNMLF: $954.09M
AQST [@Pharmaceuticals: Generic] is valued at $429.45M. GNMLF’s [@Pharmaceuticals: Generic] market capitalization is $954.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.17B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileGNMLF’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • GNMLF’s FA Score: 1 green, 4 red.
According to our system of comparison, both AQST and GNMLF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while GNMLF’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 6 bearish.
  • GNMLF’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, GNMLF is a better buy in the short-term than AQST.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а -43.50% price change this week, while GNMLF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.60%. For the same industry, the average monthly price growth was +8.77%, and the average quarterly price growth was +19.20%.

Reported Earning Dates

AQST is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMLF($954M) has a higher market cap than AQST($429M). GNMLF YTD gains are higher at: 0.000 vs. AQST (-45.511). GNMLF has higher annual earnings (EBITDA): 3.67B vs. AQST (-51.38M). GNMLF has more cash in the bank: 2.4B vs. AQST (129M). AQST has less debt than GNMLF: AQST (41.4M) vs GNMLF (7.34B). GNMLF has higher revenues than AQST: GNMLF (18.2B) vs AQST (43.4M).
AQSTGNMLFAQST / GNMLF
Capitalization429M954M45%
EBITDA-51.38M3.67B-1%
Gain YTD-45.5110.000-
P/E RatioN/A11.50-
Revenue43.4M18.2B0%
Total Cash129M2.4B5%
Total Debt41.4M7.34B1%
FUNDAMENTALS RATINGS
AQST vs GNMLF: Fundamental Ratings
AQST
GNMLF
OUTLOOK RATING
1..100
5043
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
5
Undervalued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
10070
PRICE GROWTH RATING
1..100
6551
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
3565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMLF's Valuation (5) in the null industry is somewhat better than the same rating for AQST (39) in the Pharmaceuticals Major industry. This means that GNMLF’s stock grew somewhat faster than AQST’s over the last 12 months.

GNMLF's Profit vs Risk Rating (92) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that GNMLF’s stock grew similarly to AQST’s over the last 12 months.

GNMLF's SMR Rating (70) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that GNMLF’s stock grew similarly to AQST’s over the last 12 months.

GNMLF's Price Growth Rating (51) in the null industry is in the same range as AQST (65) in the Pharmaceuticals Major industry. This means that GNMLF’s stock grew similarly to AQST’s over the last 12 months.

GNMLF's P/E Growth Rating (94) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that GNMLF’s stock grew similarly to AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTGNMLF
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
11%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
23%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
21%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
23%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
19%
Advances
ODDS (%)
Bullish Trend 18 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
22%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signal:
Gain/Loss:
GNMLF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NQCCX4.110.01
+0.24%
Nuveen Large Cap Value Opportunities C
TIGVX25.16-0.05
-0.20%
Thornburg International Growth R3
SLASX42.78-0.18
-0.42%
Selected American Shares S
MFRLX44.14-0.20
-0.45%
MFS Research R1
DFDPX37.42-0.17
-0.45%
DF Dent Premier Growth Investor

AQST and

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with SXTC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then SXTC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+2.92%
SXTC - AQST
40%
Loosely correlated
-3.70%
HROW - AQST
30%
Poorly correlated
+2.06%
ESPR - AQST
29%
Poorly correlated
-2.12%
ETON - AQST
27%
Poorly correlated
-0.38%
ACET - AQST
26%
Poorly correlated
N/A
More

GNMLF and

Correlation & Price change

A.I.dvisor tells us that GNMLF and AQST have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNMLF and AQST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMLF
1D Price
Change %
GNMLF100%
N/A
AQST - GNMLF
21%
Poorly correlated
+2.92%
LVRLF - GNMLF
20%
Poorly correlated
-11.79%
VEXTF - GNMLF
20%
Poorly correlated
-1.71%